Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

New Indian Drug Policy Expected To Be Approved At Next Meeting

This article was originally published in PharmAsia News

Executive Summary

India's new pharmaceutical policy is expected to be approved at its next meeting, although the date for the meeting has not been set. The Union Minister of Chemical and Fertilisers is considering a draft policy that contains some disagreements between the Chemicals Ministry and the pharmaceutical industry in India over price controls and other provisions. Under the policy as drafted so far, the list of essential medicines under price controls would increase from 74 to 354. The industry has objected to the added inclusions, arguing such a move would adversely affect research and development. (Click here for more

Latest Headlines
See All
UsernamePublicRestriction

Register

SC067808

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel